Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: C09AA02

Aqumeldi(Enalapril (maleate))

Heart Failure

Marketing Authorisation Holder: Proveca Pharma Limited

EMA Authorisation: 15/11/2023

INN: enalapril maleate

Indication

Treatment of heart failure.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Aqumeldi — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.